-
Clin Cancer Res: A new CIP2A mutant (NOCIVA) that can predict TKI resistance in myeloid leukemia
Time of Update: 2021-03-20
reported a CIP2A splice mutant NOCIVA (new) in the article “Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias” published in the journal “Clinical Cancer Research”.
CCR-20-3679" target="_blank" rel="noopener">Discovery of a Novel CIP2A Variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias .
-
Eur Radiol: Can DCE-MRI predict the chemotherapy response and survival rate of primary central nervous system lymphoma?
Time of Update: 2021-03-20
Evaluated the role of dynamic-enhanced magnetic resonance imaging (DCE-MRI) in predicting the chemotherapy response and clinical prognosis of patients with primary central nervous system lymphoma (PCNSL), and provided clinical images for predicting the therapeutic effect of PCNSL patients before treatment Student biomarkers.
-
NEJM: Application of Whole Genome Sequencing vs. Cytogenetic Testing in Risk Stratification of Patients with Myeloid Tumors
Time of Update: 2021-03-20
Gene mapping analysis is very important for the risk stratification of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), and cytogenetic analysis is usually used.
Recently, researchers have investigated the application of whole-genome sequencing in the risk stratification of patients with myeloid tumors.
-
J Clin Oncol: PI3Kδ/CK1ε dual inhibitor Umbralisib for the treatment of relapsed/refractory indolent lymphoma
Time of Update: 2021-03-20
03433" target="_blank" rel="noopener">Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma .
03433" target="_blank" rel="noopener">Umbralisib, a Dual PI3Kδ / CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma in this message
-
JAMA: Immunogenicity of a single dose of SARS-CoV-2 mRNA vaccine in recipients of solid organ transplantation
Time of Update: 2021-03-20
Patients who received mRNA-1273 were more likely to develop an antibody response than those who received BNT162b2 (In this study on the immunogenicity of the first dose of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients, most subjects did not develop a significant anti-spike antibody response.
-
JACC: Double-stranded small interfering RNA Inclisiran can effectively reduce low-density lipoprotein cholesterol in patients with many types of hypercholesterolemia!
Time of Update: 2021-03-20
In summary, the pooled analysis shows that on the basis of the maximum tolerated dose of statin ± other LDL-C lowering drugs, Inlisiran, used twice a year, can reduce the risk of heterozygous familial hypercholesterolemia, ASCVD or ASCVD LDL-C in the same adult patient is an effective, safe and well-tolerated treatment.
-
JAMA Pediatr: Umbilical cord management and poor prognosis of preterm infants
Time of Update: 2021-03-20
Compared with ICC, the risk of intraventricular hemorrhage in premature infants in the UCM group (10 studies, 645 children, 22.
Compared with ICC, the risk of intraventricular hemorrhage in premature infants in the UCM group (10 studies, 645 children, 22.
-
FDA approves PEPAXTO (melphalan flubenzamide) for the treatment of relapsed and refractory multiple myeloma
Time of Update: 2021-03-19
PEPAXTO is an anti-cancer peptide-drug conjugate (PDC) that targets aminopeptidase and rapidly releases alkylating agents into tumor cells.
PEPAXTO is an anti-cancer peptide-drug conjugate (PDC) that targets aminopeptidase and rapidly releases alkylating agents into tumor cells.
-
JAMA: Blinatumomab can improve the event-free survival rate of high-risk children with B-cell acute lymphoblastic leukemia who relapse for the first time
Time of Update: 2021-03-19
Researchers in children recently investigated the effect of replacing consolidation chemotherapy with Blinatumomab on the event-free survival rate of children with high-risk first recurrence of B-ALL before allogeneic hematopoietic stem cell transplantation.
-
BLOOD: Good news!
Time of Update: 2021-03-19
Yesterday, BLOOD released the results of a phase II study, showing that in myeloma patients who have received a median of 4 treatment routes, adding dexamethasone to ISAtuximab can increase the ORR from 23.
-
NEJM: Ide-cel is successful in phase II clinical treatment of patients with recurrent multiple myeloma
Time of Update: 2021-03-19
Researchers of Immune CAR-T recently investigated the efficacy and safety of ide-cel in patients with relapsed and refractory multiple myeloma.
Recently, researchers investigated the efficacy and safety of ide-cel in patients with relapsed and refractory multiple myeloma.
-
JAMA: Blinatumomab vs chemotherapy for children, adolescents and young patients with B-cell acute lymphoblastic leukemia who have relapsed for the first time
Time of Update: 2021-03-19
For children, adolescents, and young patients who have relapsed for the first time in B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improves patients The effects of disease-free survival and 2-year survival are not significant.
-
NICE: European mantle cell lymphoma patients will fully benefit from CAR-T cell therapy!
Time of Update: 2021-03-18
Tecartus is a CAR-T cell therapy targeting CD19 .
Tecartus is a CAR-T cell therapy targeting CD19 .
CAR-TThe new NICE guidelines point out that this treatment can be considered for patients with relapsed and refractory mantle cell lymphoma.
-
JCO: Lenalidomide + R-CHOP combination therapy failed to significantly improve PFS of ABC DLBCL
Time of Update: 2021-03-18
01366">ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma .
01366">ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma in this message
-
Cell: Under what circumstances will the iron in our body rise?
Time of Update: 2021-03-18
What is the reason?On February 18, 2021, the international academic journal Cell published an online study titled "A role of PIEZO1 in iron metabolism in mice and humans" by the Ardem Patapoutian team of the Howard Hughes Medical Institute in the United States.
-
Gene therapy LentiGlobin treats sickle cell disease, encounters Waterloo
Time of Update: 2021-03-18
Recently, the biopharmaceutical company Bluebird bio disclosed that the FDA has put its LentiGlobin gene therapy plan for sickle cell disease (SCD) on hold in the clinical stage.
diagnosisThe red blood cells of patients with sickle cell disease contain abnormal hemoglobin (a protein that carries oxygen).
-
Nat Commun: The biological and therapeutic significance of the unique subtype of acute myeloid leukemia with NPM1 mutation
Time of Update: 2021-03-18
Two subtypes are associated with patient survivalAll in all, the results of the study emphasize the heterogeneity between NPM1 mutant AML patient samples based on stem cell characteristics, and show that the addition of kinase inhibitors to the original, FLT3-ITD missing cases may have therapeutic benefits.
-
J Clin Oncol: Application of Simplified Elderly Patient Assessment Scale in DLBCL Elderly Patients
Time of Update: 2021-03-18
In view of the fact that in the oGA multivariate analysis, age greater than 80 years old has an independent correlation with OS, the researchers also developed a new simplified version of GA (sGA), which can divide patients into appropriate (55%) and inappropriate (28%) and frailty (18%), the three-year OS was 75%, 58%, and 43%, respectively.
-
Eur Radiol: How to evaluate the structure and heterogeneity of multiple myeloma?
Time of Update: 2021-03-18
Recently, a study published in the journal European Radiology showed that the use of DECT combined with texture analysis explored the correlation between the texture characteristics of myeloma DECT bone marrow imaging and the serum markers related to myeloma activity and the degree of medulla involvement.
-
Heart: The latest results of real-world analysis once again confirmed the clinical benefits and safety of non-vitamin K antagonist oral anticoagulants
Time of Update: 2021-03-18
In the randomized RCTs comparing NOACs and VKAs, NOACs showed advantages or non-disadvantages in reducing the risk of stroke or systemic embolism, with better safety, and a lower incidence of intracranial hemorrhage.
The researchers compared the risk of all-cause mortality, non-hemorrhagic stroke/systemic embolism, and major bleeding in all patients within 2 years.
